Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848791 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL3563098 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL31148623 | 0.95 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL2689039 | 0.95 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL17770867 | 0.95 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL16004565 | 0.94 | HPGD (0.46) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL31148566 | 0.94 | HPGD (0.46) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR | |
| SCHEMBL24757382 | 0.90 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NPC1HPGDEPHX1 | |
| SCHEMBL22251831 | 0.90 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NPC1HPGDEPHX1 | |
| SCHEMBL17244010 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848372-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| EP-3504214-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2020-12-02 | — | — | EP | disclosed |
| WO-2018042303-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2018-03-08 | — | — | WO | disclosed |
| EP-1740559-B1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-7847100-B2 | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Inc. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7361663-B2 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1740559-A4 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2007-10-18 | — | — | US | disclosed |
| EP-1740559-A1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103020-A1 | 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| US-20040267010-A1 | Sulfonamide compounds, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-30 | — | — | US | disclosed |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| EP-1355902-A1 | SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. | 2003-05-15 | — | — | US | disclosed |
| EP-1263726-A1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002062788-A1 | SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-08-15 | — | — | WO | disclosed |
| WO-2001034567-A1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | HSD17B10 3221/4885SMN1; SMN2 2944/4885NPC1 2752/4885 |
| US-20040267010-A1 | Sulfonamide compounds, their preparation and use | HTR7, HTR6, SIGMAR1 | HSD17B10 1634/4885SMN1; SMN2 1289/4885NPC1 2188/4885 |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | HSD17B10 3221/4885SMN1; SMN2 2944/4885NPC1 2752/4885 |
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | HSD17B10 826/4885SMN1; SMN2 1431/4885NPC1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.